Internalization and degradation of natriuretic peptide receptor-A is stimulated by ligand binding by Flora, Darcy R et al.
BioMed  Central
Page 1 of 1
(page number not for citation purposes)
BMC Pharmacology
Open Access Poster presentation
Internalization and degradation of natriuretic peptide receptor-A is 
stimulated by ligand binding
Darcy R Flora*1, Sean D Conner2 and Lincoln R Potter1,3
Address: 1Department of Pharmacology, University of Minnesota, Minneapolis, MN, USA, 2Department of Genetics, Cell Biology and 
Development, University of Minnesota, Minneapolis, MN, USA and 3Department of Biochemistry, Molecular Biology and Biophysics, University 
of Minnesota, Minneapolis, MN, USA
Email: Darcy R Flora* - flora097@umn.edu
* Corresponding author    
Background
Natriuretic peptide receptor-A (NPR-A) is a transmem-
brane receptor guanylyl cyclase that binds and mediates
the effects of atrial and B-type natriuretic peptides (ANP/
BNP). Internalization and ligand-dependent degradation
of NPR-A is controversial, in part due to the use of ligand
binding studies to predict the cellular location of the
receptor. Here, we used a more direct sequential immuno-
precipitation-western blot assay to demonstrate that long-
term ANP exposure increases NPR-A degradation in pri-
mary, immortalized, and transfected cells.
Results
A separate novel extracellular epitope antibody-binding
assay indicated that NPR-A is internalized under basal
conditions and that this rate is increased about two-fold
by ANP exposure. siRNA knock down of clathrin and
dominant negative inhibition of dynamin failed to inhibit
ANP-dependent NPR-A degradation, whereas dominant
negative dynamin expression reduced the rate of NPR-A
internalization about 40%.
Conclusion
These data indicate that NPR-A is basally internalized by a
dynamin-dependent pathway and that prolonged ANP
exposure stimulates both NPR-A internalization and deg-
radation.
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